EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

Hanna W van Steenbergen, Frank Doornkamp, Stefano Alivernini, John Backlund, Catalin Codreanu, Stanley B Cohen, Bernard Combe, Andrew P Cope, Kevin D Deane, Bryant R England, Marie Falahee, Pascal H P de Jong und 20 weitere

Annals of the Rheumatic Diseases · 2025-09 · 84 (9) · 1445-1457

DOI: 10.1016/j.ard.2025.01.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025-09. Verfasst von Hanna W van Steenbergen und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Arthralgia. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aid for Cancer Research, EULAR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but a validated risk stratification method is lacking. This work was undertaken to develop a risk stratification method for persons presenting with arthralgia considered to be at risk of RA. METHODS: A joint European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) expert committee was established. Risk factor and outcome data from 10 arthralgia cohorts (including clinically suspect arthralgia and autoantibody-positive arthralgia) were studied. The work focused on differentiating the risk of progression to clinically apparent inflammatory arthritis (IA) within 1 year, using clinical and serologic variables, without and with subclinical joint inflammation detected by ultrasound (US) or magnetic resonance imaging (MRI). Developing RA according to the 2010 EULAR/ACR criteria within 1 year was a secondary outcome. A set of validated risk stratification criteria was developed. RESULTS: Using data from 2293 symptomatic at-risk individuals, a stratification method was derived consisting of 6 clinical and serologic variables (morning stiffness, patient-reported joint swelling, difficulty making a fist, C-reactive protein, rheumatoid factor, and anti-citrullinated peptide antibody) yielding an area under the curve (AUC) of 0.80 (95% CI, 0.77-0.83) for IA development. The inclusion of US variables did not increase the discriminative ability. When MRI-detected subclinical inflammation variables were included, the AUC was 0.87 (95% CI, 0.82-0.90). In the presence of clinical, serologic, and MRI variables, a sensitivity and specificity of >75% was achieved. For RA development, the AUC of the criteria with MRI was 0.93 (95% CI, 0.90-0.97). CONCLUSIONS: EULAR/ACR risk stratification criteria have been developed for people with arthralgia in secondary care who are considered at risk for RA. They can be applied in the absence or presence of imaging data and have been developed to define homogeneous risk groups for future prevention trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidArthralgiaHumansRisk AssessmentFemaleMaleMiddle AgedDisease ProgressionAdultRheumatoid FactorMagnetic Resonance ImagingAnti-Citrullinated Protein AntibodiesAgedAutoantibodiesC-Reactive ProteinRisk FactorsBiomarkers

Substanzen

Rheumatoid FactorAnti-Citrullinated Protein AntibodiesAutoantibodiesC-Reactive ProteinBiomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands.
  • Division of Rheumatology, Fondazione Policlinico Universitário A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico-Università Cattolica del Sacro Cuore, Rome, Italy.
  • At-risk participant.
  • Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania.
  • University of Texas Southwestern Medical School, Dallas, TX, USA.

Förderung

  • Aid for Cancer Research
  • EULAR

Zitieren

APA

van Steenbergen, H. W., Doornkamp, F., Alivernini, S., Backlund, J., Codreanu, C., Cohen, S. B., Combe, B., Cope, A. P., Deane, K. D., England, B. R., Falahee, M., de Jong, P. H. P., Kleyer, A., Lacaille, D., Maat, B., Mankia, K., van Mulligen, E., Nagy, G., O'Neil, L. J., …, & van der Helm-van Mil, A. H. M. (2025). EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. Annals of the Rheumatic Diseases, 84(9), 1445-1457. https://doi.org/10.1016/j.ard.2025.01.021

Vancouver

van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, et al. EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. Annals of the Rheumatic Diseases. 2025;84(9):1445-1457. doi:10.1016/j.ard.2025.01.021

BibTeX
@article{vanSteenbergen2025,
  author = {van Steenbergen, Hanna W and Doornkamp, Frank and Alivernini, Stefano and Backlund, John and Codreanu, Catalin and Cohen, Stanley B and Combe, Bernard and Cope, Andrew P and Deane, Kevin D and England, Bryant R and Falahee, Marie and de Jong, Pascal H P and Kleyer, Arnd and Lacaille, Diane and Maat, Bertha and Mankia, Kulveer and van Mulligen, Elise and Nagy, György and O'Neil, Liam J and Rodamaker, Linda and Sahbudin, Ilfita and van Schaardenburg, Dirkjan and Sepriano, Alexandre and da Silva, Jose A P and De Smet, Lukas and Sparks, Jeffrey A and Steyerberg, Ewout W and Studenic, Paul and Wethington, Elisabeth and Landewé, Robert L and Raza, Karim and van der Helm-van Mil, Annette H M},
  title = {EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {9},
  pages = {1445--1457},
  doi = {10.1016/j.ard.2025.01.021}
}
Kostenlos starten →